Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BDL:CHWGR Stock Report

Market Cap: US$4.8b

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Past Earnings Performance

Past criteria checks 5/6

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt has been growing earnings at an average annual rate of 23.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 11.8% per year. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's return on equity is 17.3%, and it has net margins of 25.2%.

Key information

23.5%

Earnings growth rate

23.7%

EPS growth rate

Pharmaceuticals Industry Growth21.0%
Revenue growth rate11.8%
Return on equity17.3%
Net Margin25.2%
Next Earnings Update28 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BDL:CHWGR Revenue, expenses and earnings (HUF Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24839,601211,635207,70289,283
30 Jun 24811,415229,129203,36384,358
31 Mar 24798,937187,874199,58483,924
31 Dec 23805,158158,850196,61978,344
30 Sep 23825,94895,563201,66778,574
30 Jun 23855,211123,426199,70477,387
31 Mar 23844,351157,720191,46975,290
31 Dec 22802,755169,076182,35075,109
30 Sep 22755,061242,521165,81668,730
30 Jun 22694,772198,297155,13566,489
31 Mar 22657,758149,792146,77362,419
31 Dec 21630,595139,626143,26161,005
30 Sep 21604,708114,689139,57559,304
30 Jun 21584,88799,067136,05956,079
31 Mar 21566,244102,570132,52554,418
31 Dec 20566,776104,683133,76653,977
30 Sep 20555,12468,482134,35855,110
30 Jun 20544,96468,130137,59653,745
31 Mar 20527,60854,123144,86652,273
31 Dec 19507,79447,135145,28148,860
30 Sep 19490,66849,451144,04346,258
30 Jun 19462,57636,071143,72043,363
31 Mar 19453,15142,857141,65040,903
31 Dec 18445,48435,348139,65440,545
30 Sep 18434,07811,939140,52341,576
30 Jun 18441,99718,899139,25340,768
31 Mar 18445,6262,997139,41241,027
31 Dec 17444,3568,885138,25639,903
30 Sep 17439,82268,291137,88237,763
30 Jun 17429,20766,829136,12136,317
31 Mar 17413,02174,992131,93235,489
31 Dec 16389,69066,200127,90335,153
30 Sep 16372,68952,016122,48632,401
30 Jun 16368,53944,525120,79233,588
31 Mar 16366,88950,419118,31833,813
31 Dec 15365,22053,863117,70734,822
30 Sep 15366,63140,482117,11040,072
30 Jun 15362,90339,300119,71442,380
31 Mar 15353,08030,652119,71342,996
31 Dec 14353,70924,950121,31543,666
30 Sep 14355,04331,723126,41143,069
30 Jun 14348,76837,367123,44642,308
31 Mar 14354,34633,058126,46741,371
31 Dec 13351,88642,766126,31740,800

Quality Earnings: CHWGR has high quality earnings.

Growing Profit Margin: CHWGR's current net profit margins (25.2%) are higher than last year (11.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: CHWGR's earnings have grown significantly by 23.5% per year over the past 5 years.

Accelerating Growth: CHWGR's earnings growth over the past year (121.5%) exceeds its 5-year average (23.5% per year).

Earnings vs Industry: CHWGR earnings growth over the past year (121.5%) exceeded the Pharmaceuticals industry 9.5%.

Return on Equity

High ROE: CHWGR's Return on Equity (17.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 12:46
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Simon MatherBarclays
Samuel EnglandBerenberg
Victoria LambertBerenberg